US demand to rise 4.5% annually through 2014
Demand for wipes, both consumer and industrial, is forecast to increase 4.5 percent per annum to $2.3 billion in 2014. Wipes will continue to benefit from features such as ease-of-use, disposability, portability, and reduced risk of crosscontamination. Nevertheless, growth will decelerate from rates achieved during the 2004 to 2009 period due to increasing market maturity and a shift in preferences to more environmentally friendly consumer goods and cleaning methods. In response to the “green” trend, wipes manufacturers will continue to develop more environmentally friendly products, such as those that are biodegradable.
Hand, body wipes to further penetrate consumer market
Convenience, consumer acceptance and innovation will remain driving forces in the consumer market, with household cleaning, hand and body, and a number of other, small volume consumer wipes projected to register the strongest gains. Growth in household care wipes, such as general purpose disinfectant wipes, will be propelled by the appeal of one-step, disposable wipes that provide a quick and convenient format for household cleaning chores. These wipes also offer a fast and easy cleaning alternative for consumers with little free time. Hand and body wipes, such as bathroom hygiene and general purpose bathing, will enjoy increased market penetration. For example, the concept of wet bathroom tissue as part of a standard bathroom routine is gaining acceptance. General purpose bathing wipes are also gaining acceptance among individuals who are bedridden or find it difficult to enter and exit a bathtub. Nevertheless, baby wipes will remain the top selling type of consumer wipe. Demand for baby wipes will continue to suffer due to market maturity, as well as continued replacement by newer, task-specific wipes in non-diaper applications, where baby wipes once enjoyed considerable popularity.
Manufacturing, health care wipes to remain largest industrial wipes segments
After suffering from slower sales during the recession that began in December 2007, the industrial wipes market will benefit from a rebound in manufacturing activity through 2014. As such, wipes geared towards the manufacturing market are projected to achieve the most rapid gains through the forecast period. In addition to a more favorable economic climate, demand for industrial wipes will benefit from new product innovations and expanding applications. Among industrial wipes, manufacturing and health care types will remain the largest segments, with special purpose products such as clean room and surface preparation wipes and personal bathing wipes projected to see the fastest growth.
Surfactants to see fastest gains in chemical materials
Advances for the chemicals that saturate or are deposited into wipes will derive from the increasing diversity of chemical formulations adapted to a wipes format as companies seek to take advantage of the strong consumer interest generated by these convenient, and relatively new, products. Surfactants will experience the fastest gains, resulting from an ongoing shift away from solvent formulations.Furthermore, surfactants offering biocidal properties will drive overall value gains due to increasing concerns regarding bacterial contamination in industrial and consumer applications.
Study coverage
Details on these and other key findings are available in Wipes, a new Freedonia industry study priced at $4900. It presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by market and raw material. In addition, the study considers market environment factors, evaluates company market share data and profiles 35 industry competitors, including Kimberly-Clark, Nice-Pak and Procter & Gamble.
For more please visit
http://www.bharatbook.com/detail.asp?id=167435&rt=Wipes-to-2014.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Showing posts with label Healthcare. Show all posts
Showing posts with label Healthcare. Show all posts
Monday, January 3, 2011
Wednesday, December 29, 2010
Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential
The leading business intelligence provider, has released its latest research, “Oncology Market in India to 2017 – Limited Patient Affordability for High Priced Biologics Lowers Market Potential”, which provides insights into oncology sales and price forecasts until 2017. The report also examines the Indian oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).
Scope
The report covers:
- Data and analysis on the oncology market in India.
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the oncology market includes both Indian players and foreign players.
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Indian oncology market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
- Build effective strategies to launch their pipeline products by identifying potential of the market.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying each indication’s growth rate.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Companies Mentioned
Dr. Reddy’s Lab
Piramal Healthcare
Biocon Limited
Cipla Ltd.
Sanofi-Aventis
F. Hoffmann-La Roche Ltd/Genentech, Inc.
AstraZeneca
GlaxoSmithKline
For more please visit
http://www.bharatbook.com/detail.asp?id=167044&rt=Oncology-Market-in-India-to-2017-Limited-Patient-Affordability-for-High-Priced-Biologics-Lowers-Market-Potential.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Scope
The report covers:
- Data and analysis on the oncology market in India.
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the oncology market includes both Indian players and foreign players.
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Indian oncology market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
- Build effective strategies to launch their pipeline products by identifying potential of the market.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying each indication’s growth rate.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Companies Mentioned
Dr. Reddy’s Lab
Piramal Healthcare
Biocon Limited
Cipla Ltd.
Sanofi-Aventis
F. Hoffmann-La Roche Ltd/Genentech, Inc.
AstraZeneca
GlaxoSmithKline
For more please visit
http://www.bharatbook.com/detail.asp?id=167044&rt=Oncology-Market-in-India-to-2017-Limited-Patient-Affordability-for-High-Priced-Biologics-Lowers-Market-Potential.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Contraceptives Market to 2016 - Demand for Long Acting Birth Control Pills Encourages Growth in Hormonal Contraceptives Market
The leading business intelligence provider, has released its latest research “Contraceptives Market to 2016 - Demand for Long Acting Birth Control Pills Encourages Growth in Hormonal Contraceptives Market” which provides insight about contraceptive sales and price forecasts until 2016. The report also delves deep into global contraceptive treatment usage patterns. Further, contraceptive markets in the key geographies of the US, top five EU countries and Japan are also covered in the report. The report also includes details about contraceptive R&D pipelines and potential future blockbuster products. The report provides in-depth analysis of the main contraceptive classes, which includes oral contraceptives, injectables and topical contraceptives. Furthermore, it includes market forecasts and treatment usage patterns for each therapeutic class. The report also explores the competitive landscape, with a competitive analysis of the top companies in the market. Finally, a key trend analysis of mergers and acquisitions, and licensing agreements in the contraceptives market is also included.
Scope
The scope of this report includes:
- Data and analysis of the contraceptives market in the leading geographies which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the contraceptives market from 2001 to 2009, with forecasts to 2016.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy, sales volumes and treatment usage patterns, such as disease populations, treatment seeking populations, diagnosis populations and prescription populations.
- Key drivers and restraints that have had significant impact on the market.
- Competitive landscape of the global contraceptives market including benchmarking of the top companies. The key companies studied in this report are Merck/Schering-Plough, Pfizer/Wyeth, Johnson and Johnson, Bayer and Warner Chilcott
- Key M&A and licensing agreements that have taken place between 2008 and 2009 in the contraceptives market
Reasons to buy
The report will aid business development and help marketing executives strategizing product launches:
- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
For more please visit
http://www.bharatbook.com/detail.asp?id=167043&rt=Contraceptives-Market-to-2016-Demand-for-Long-Acting-Birth-Control-Pills-Encourages-Growth-in-Hormonal-Contraceptives-Market.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Scope
The scope of this report includes:
- Data and analysis of the contraceptives market in the leading geographies which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the contraceptives market from 2001 to 2009, with forecasts to 2016.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy, sales volumes and treatment usage patterns, such as disease populations, treatment seeking populations, diagnosis populations and prescription populations.
- Key drivers and restraints that have had significant impact on the market.
- Competitive landscape of the global contraceptives market including benchmarking of the top companies. The key companies studied in this report are Merck/Schering-Plough, Pfizer/Wyeth, Johnson and Johnson, Bayer and Warner Chilcott
- Key M&A and licensing agreements that have taken place between 2008 and 2009 in the contraceptives market
Reasons to buy
The report will aid business development and help marketing executives strategizing product launches:
- Build effective strategies to launch pipeline products, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of the top competitors.
- Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
For more please visit
http://www.bharatbook.com/detail.asp?id=167043&rt=Contraceptives-Market-to-2016-Demand-for-Long-Acting-Birth-Control-Pills-Encourages-Growth-in-Hormonal-Contraceptives-Market.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Tuesday, December 28, 2010
Global Pharmaceutical Market Forecast to 2012
The pharmaceutical market worldwide, after having experienced exponential growth over the past few years, is now witnessing a slump. This decline in global pharma market is largely attributed to the patent expiry of key blockbusters together with saturation in key pharma markets such as the US and Western Europe. Meanwhile, pharma markets in some developing regions like Asia and Latin America have been continuously witnessing robust growth rate in last few years on account of increasing prevalence of diseases, rising healthcare spending and increasing affordability. Overall, these markets enjoy good growth potential in coming few years.
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Global Pharmaceutical Market Forecast to 2012
The pharmaceutical market worldwide, after having experienced exponential growth over the past few years, is now witnessing a slump. This decline in global pharma market is largely attributed to the patent expiry of key blockbusters together with saturation in key pharma markets such as the US and Western Europe. Meanwhile, pharma markets in some developing regions like Asia and Latin America have been continuously witnessing robust growth rate in last few years on account of increasing prevalence of diseases, rising healthcare spending and increasing affordability. Overall, these markets enjoy good growth potential in coming few years.
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
According to our latest research “Global Pharmaceutical Market Forecast to 2012”, global pharma industry is projected to grow at a CAGR of around 6% during 2010-2012. The growth will be driven by low cost factor, increasing prevalence of diseases worldwide and rising per capita income of consumers. Our research identifies that sales of generic drugs will emerge as the most prominent segment of the pharma market over the forecast period, indicating large opportunities for generics manufacturers to tap.
Our regional level analysis finds that the pharma industry is growing at a rapid rate in the emerging countries like India, China, Brazil, Russia, among others, while a slowdown in the growth has been encountered in the US and Western European countries. Besides this, we have found that growing inorganically via means of Mergers & Acquisitions has emerged as the most viable way for the companies to expand/extend their reach at a faster rate and maintain their revenues. We anticipate this trend to continue in near future also.
“Global Pharmaceutical Market Forecast to 2012” provides a comprehensive analysis of every major pharmaceutical market worldwide. North America, Latin America, Europe, Asia-Pacific and Africa have been selected as the most important regions to be presented in this report. The report contains statistical and analytical information on each of these markets, covering their current market size, demand and healthcare statistics. It also features analysis of future directions, supplemented with facts and figures.
For more please visit
http://www.bharatbook.com/detail.asp?id=83239&rt=Global-Pharmaceutical-Market-Forecast-to-2012.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Emerging Pharmaceutical Markets Globally
The growth in pharma markets in emerging countries has outpaced the overall growth of the global pharma market. The growth in these markets is being driven by rapidly growing economies of these countries, increasing per capita income, increasing prevalence of lifestyle diseases, and low-cost factors. In 2008, pharma market in E7 countries (Brazil, Russia, China, India, Turkey, Mexico and Indonesia) was estimated at around US$ 96 Billion, and it is expected that high growth in these markets will help these countries increase their share in global pharma market.
According to our new research study on the sector titled “Emerging Pharmaceutical Markets Globally”, the pharmaceutical market in the abovementioned emerging countries is projected to grow at a CAGR of around 14.7% during 2009-2012. Currently, these markets are characterized by rapid urbanization, which has led to the growth in prevalence of lifestyle diseases.
Our report has found that China has the largest pharma market out of these seven countries, followed by Brazil, Mexico and India. However, the maximum growth in future is expected to be in Russia and China due to strong government support. Besides, we have identified that most of the E7 pharmaceutical markets are still dominated by acute therapies, but the growth rate of chronic therapies far exceeds that of acute therapies. Thus, the therapy mix of the market in the next few years will be much different from what it is today.
The research study provides extensive and coherent information about pharma markets in emerging countries. It highlights several emerging opportunities growing in line with development of pharma markets in E7 countries. The research study gives detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains all the key details that will help clients to draw up market strategies and assess opportunity areas for their success in these emerging pharma markets.
For more please visit
http://www.bharatbook.com/detail.asp?id=73228&rt=Emerging-Pharmaceutical-Markets-Globally.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
According to our new research study on the sector titled “Emerging Pharmaceutical Markets Globally”, the pharmaceutical market in the abovementioned emerging countries is projected to grow at a CAGR of around 14.7% during 2009-2012. Currently, these markets are characterized by rapid urbanization, which has led to the growth in prevalence of lifestyle diseases.
Our report has found that China has the largest pharma market out of these seven countries, followed by Brazil, Mexico and India. However, the maximum growth in future is expected to be in Russia and China due to strong government support. Besides, we have identified that most of the E7 pharmaceutical markets are still dominated by acute therapies, but the growth rate of chronic therapies far exceeds that of acute therapies. Thus, the therapy mix of the market in the next few years will be much different from what it is today.
The research study provides extensive and coherent information about pharma markets in emerging countries. It highlights several emerging opportunities growing in line with development of pharma markets in E7 countries. The research study gives detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, key drivers and restraints. It contains all the key details that will help clients to draw up market strategies and assess opportunity areas for their success in these emerging pharma markets.
For more please visit
http://www.bharatbook.com/detail.asp?id=73228&rt=Emerging-Pharmaceutical-Markets-Globally.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Thursday, December 16, 2010
Healthcare Industry in United States
Health care in the United States is provided by many separate legal entities. Current estimates put US healthcare spending at approximately 15% of GDP, which is the highest in the world. The United States spends the highest percentage of health care costs on pharmaceuticals in the world. The health share of gross domestic product (GDP) is expected to hold steady in 2006 before resuming its historical upward trend, reaching 19.6 percent of GDP by 2016. In the United States, around 85% of citizens have health insurance, either through their employer or purchased individually.
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Healthcare Industry in United States
Health care in the United States is provided by many separate legal entities. Current estimates put US healthcare spending at approximately 15% of GDP, which is the highest in the world. The United States spends the highest percentage of health care costs on pharmaceuticals in the world. The health share of gross domestic product (GDP) is expected to hold steady in 2006 before resuming its historical upward trend, reaching 19.6 percent of GDP by 2016. In the United States, around 85% of citizens have health insurance, either through their employer or purchased individually.
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The federal government does not guarantee universal health care to all its citizens, but certain publicly-funded health care programs help to provide for some of the elderly, disabled, and the poor and federal law ensures public access to emergency services regardless of ability to pay. Those without health insurance coverage are expected to pay privately for medical services. Health insurance is expensive and medical bills are overwhelmingly the most common reason for personal bankruptcy in the United States.
This report from Aruvian's R'search on the Healthcare Industry in United States looks at the overall industry, starting with the basic market analysis, and leading on to analyzing the major issues facing the industry today. The report contains two Michael Porter’s Five Forces Analysis, and an industry analysis through the PEST framework. A look at the major players, growth drivers, the issue of GPOs in the healthcare industry, outsourcing trends, role of IT in the industry, and a lot more factors are looked at in this report.
Table of Contents :
A. Executive Summary
B. Analyzing the Industry
Defining the Market
Business Segments
Industry Scenario
Investments in the Industry
C. Growth Drivers
D. Barriers to Industry Growth
E. Looking at the Healthcare Workforce
Types of Jobs Available
Workforce Issues
Role of US Department of Labor
F. Group Purchasing Organizations & the Healthcare Industry
Overview
Financial Burden of GPO Activities
The Economic Impact of GPOs on the Healthcare Industry
Healthcare Group Purchasing Industry Initiative (HGPII)
Growth Trends of GPOs
Structure of GPOs
G. Michael Porter’s Analysis of GPOs in the Healthcare Industry
Intra-Industry Competition
Oligopolistic Competition
Market Domination by GPOs
New Entrants & Threat of Competition
Bargaining Power of Suppliers & Buyers
H. Michael Porter’s Analysis of the US Healthcare Industry
Power of Suppliers & Buyers
Competition
Threat of New Entrants
Threat of Industry Substitution
I. Health Care Industry Evolution and the Role of Information Technology
J. Outsourcing Trends in the Healthcare Industry
K. Budget Crises and the Impact on the Healthcare Industry
L. Analyzing Industry Growth
M. Looking at Competition
N. Analyzing the Industry through a PEST Framework
Political Features
Economic Features
Social Features
Technological Features
O. Waste & Emissions Profile of the US Healthcare Industry
Biohazardous Waste
Hazardous Chemical Waste
Wastewater Discharge Data for the Healthcare Industry
Air Emissions from the Healthcare Industry
Municipal Solid Waste
P. Analysis of Leading Market Players
AmerisourceBergen Corporation
Amsurg Corp
Advanced Medical Optics Inc
Allied Healthcare Group
BJC Healthcare
Cardinal Health
McKesson Corporation
Q. Directions for Industry Players
R. Future Outlook
S. Appendix
T. Glossary of Terms
For more please visit
http://www.bharatbook.com/detail.asp?id=161393&rt=Healthcare-Industry-in-United-States.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Wednesday, December 15, 2010
Analyzing the Global Pharmaceutical Industry
The birth origins of the Pharmaceutical Industry can be traced back to more humble antecedents than just chemistry labs. The earliest incidents of recognition of the antiseptic properties of the dyestuffs is around the late 19th century. The invention of penicillin can yet be recognized as a major milestone for the emergent industry which firmly consolidated its R&D efforts in the 1950’s. Further in the 1960’s the patent regulation support gave a further impetus to the industry in new discoveries and relaxed controls on clinical development with the booming spend on healthcare as economies boomed globally.
The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with inter continental treatment demand of patients being serviced from often one or two mega research centers in the continent.
By contribution of size, the pharmaceutical industry is majorly dominant at the US, Europe and Japan. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.
The marketing aggressiveness of US-based companies has placed them at the top of the pile, being followed closely by the European sector. Countries like the UK, France and Denmark each have at least two pharmaceutical companies in their respective ten largest corporate enterprises.
Aruvian's R'search’s report – Analyzing the Global Pharmaceutical Industry - presents a complete analysis of the global pharmaceutical industry by setting up a industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry , competitive activity and the overall market outlook.
The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy – store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.
The R&D initiatives practiced by the industry, which are often used to ward off competition as well as developing new alliances, are explained as a major thrust area powering the industry growth in this report. The report presents an invaluable input in the form of analyzing the drug development and lifecycle of a drug from discovery to discontinuation and the kind of R&D costs which are involved in developing that drug. The crucial supportive role of the patent system which energizes innovation in the industry and further efforts on genomics is also elaborated in the report.
The need for corporate social responsibility in the pharma sector which serves as a safeguard for ensuring socially ethical drug development is also provided in this report. The report delves deeper into the pricing questions that always face any global pharmaceutical company wherein the constant tug between reasonability and deriving product costs in conjunction with the objectives of the respective country’s government. The report also throws light on the issues faced by pharmaceutical majors in the developing countries wherein the effects of TRIPS and the pricing of medicines are constantly on the resolution agendas of these companies.
The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report.
The report takes a critical view on the irresponsible drug promotion and advertising practiced by some pharma companies in this majorly ethical business and the issue of protecting IPR’s in the global marketplace.
An interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally along with which the report presents a country wise analysis of the pharmaceutical markets spread globally and their respective industry dynamics which includes a profiling of the major global industry players.
For more please visit
http://www.bharatbook.com/detail.asp?id=161691&rt=Analyzing-the-Global-Pharmaceutical-Industry.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with inter continental treatment demand of patients being serviced from often one or two mega research centers in the continent.
By contribution of size, the pharmaceutical industry is majorly dominant at the US, Europe and Japan. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.
The marketing aggressiveness of US-based companies has placed them at the top of the pile, being followed closely by the European sector. Countries like the UK, France and Denmark each have at least two pharmaceutical companies in their respective ten largest corporate enterprises.
Aruvian's R'search’s report – Analyzing the Global Pharmaceutical Industry - presents a complete analysis of the global pharmaceutical industry by setting up a industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry , competitive activity and the overall market outlook.
The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy – store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.
The R&D initiatives practiced by the industry, which are often used to ward off competition as well as developing new alliances, are explained as a major thrust area powering the industry growth in this report. The report presents an invaluable input in the form of analyzing the drug development and lifecycle of a drug from discovery to discontinuation and the kind of R&D costs which are involved in developing that drug. The crucial supportive role of the patent system which energizes innovation in the industry and further efforts on genomics is also elaborated in the report.
The need for corporate social responsibility in the pharma sector which serves as a safeguard for ensuring socially ethical drug development is also provided in this report. The report delves deeper into the pricing questions that always face any global pharmaceutical company wherein the constant tug between reasonability and deriving product costs in conjunction with the objectives of the respective country’s government. The report also throws light on the issues faced by pharmaceutical majors in the developing countries wherein the effects of TRIPS and the pricing of medicines are constantly on the resolution agendas of these companies.
The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report.
The report takes a critical view on the irresponsible drug promotion and advertising practiced by some pharma companies in this majorly ethical business and the issue of protecting IPR’s in the global marketplace.
An interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally along with which the report presents a country wise analysis of the pharmaceutical markets spread globally and their respective industry dynamics which includes a profiling of the major global industry players.
For more please visit
http://www.bharatbook.com/detail.asp?id=161691&rt=Analyzing-the-Global-Pharmaceutical-Industry.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Tuesday, December 14, 2010
Home Healthcare Market
Home healthcare equipment is mainly driven by the growing ageing population who prefer to receive care at their homes. Increasing hospitalization costs is another important factor which is driving the demand for low costs alternatives which has led to the growth of the home healthcare facilities for the elderly, sick and disabled in the country. This market in the US has become a fast-growing competitive market. The aging US population is estimated to reach 47 million which would be one of the main drivers of US home health care market.
The home healthcare segment contributes significantly to the US economy. The spending on the healthcare industry in the US market is more than any other country in the world. Cost effectiveness, privacy and the comfort of receiving treatments at home along with several new innovations in treatments and easy availability has driven the demand for home healthcare services, thereby leading to an increase in the number of home healthcare agencies in the country.
This report also discusses about the home dialysis market which is driven by increasing diabetes patients, rising hypertension, and rising baby boomers. Home care is quite cost effective and elderly population want to handle everything independently which again helps in boosting the growth of home care in the US.
Table of Contents :
Home healthcare Industry Overview
Market Segment Overview
Respiratory Therapy
Dialysis Market
Infusion Therapy
Drivers of each segment
Discussion about the Cost advantage with different segments
Important Trends observed in home health
Major Challenges and Opportunities available to players
Compnay Profilin of Major Players(Invacare, NxStage etc)
For more please visit
http://www.bharatbook.com/detail.asp?id=160296&rt=Home-Healthcare-Market1.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
The home healthcare segment contributes significantly to the US economy. The spending on the healthcare industry in the US market is more than any other country in the world. Cost effectiveness, privacy and the comfort of receiving treatments at home along with several new innovations in treatments and easy availability has driven the demand for home healthcare services, thereby leading to an increase in the number of home healthcare agencies in the country.
This report also discusses about the home dialysis market which is driven by increasing diabetes patients, rising hypertension, and rising baby boomers. Home care is quite cost effective and elderly population want to handle everything independently which again helps in boosting the growth of home care in the US.
Table of Contents :
Home healthcare Industry Overview
Market Segment Overview
Respiratory Therapy
Dialysis Market
Infusion Therapy
Drivers of each segment
Discussion about the Cost advantage with different segments
Important Trends observed in home health
Major Challenges and Opportunities available to players
Compnay Profilin of Major Players(Invacare, NxStage etc)
For more please visit
http://www.bharatbook.com/detail.asp?id=160296&rt=Home-Healthcare-Market1.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Sunday, July 25, 2010
Conference on Amorphous Pharmaceutical Materials
Amorphous Pharmaceutical Materials
Assessing emerging applications, methodologies, techniques and challenges.
24th - 25th January 2011, BSG Conference Centre, London, UK
Key Speakers:
Ljiljana Harding, Inhalation & Devices Centre of Emphasis, Pfizer,
Franco Sartor, Principal scientist , GlaxoSmithKline,
Sigrid Stokbroekx, Research Fellow, Johnson & Johnson Pharmaceutical R&D,
Dr. Rolf Hilfiker, Vice President Head of Department Solid-State Development, Solvias,
Roger Parker, Senior Scientist, Food Structure and Health Programme, Institute of Food Research,
Dr. Simon Gaisford, Senior Lecturer in Pharmaceutics, The School of Pharmacy, University of London
Mark Saunders, Owner, co-founder and Development Director, Kuecept,
Robert Whittock, IP/IT Practice Group, Freshfields Bruckhaus Deringer LLP,
Wouter Pors, Attorney, Bird & Bird,
Michael Gamlen, Managing Director, Pharmaceutical Development Services,
Prof. Graham Buckton, Chief Executive Officer, Pharmaterials,
Dr. Andreas Kordikowski, R&D Director, Activery Biotech,
Dr. Filipe Gaspar, Head of Particle Design, Hovione
Bertrand Gellie, Director of Organic Chemistry, European Patent Office.
Conference Introduction,
Amorphous Pharmaceutical Materials,
24th - 25th January 2011, London, UK.
With the continuous increase in the number of insoluble developmental drug molecules and growing regulatory scrutiny over pharmaceutical solids, the use of amorphous solids is steadily rising in the pharmaceutical companies. This conference combines presentations on the approaches to amorphous detection and quantitation within GSK, and clinical advice and practical tips from Pfizer and Johnson & Johnson. The biopharmaceutical implications for development of amorphous solid solution intermediates will be discussed and strategies to protect and commercialise innovations in amorphous materials will be presented.During the two days you will be exposed to several analytical strategies to protect and commercialise innovations in amorphous materials. Amorphous Pharmaceutical conference will provide an enlightening and thought-provoking forum with a series of case studies ranging from amorphous formulation to novel amorphous microparticle technology.
Reasons to register today:
• Understand the use of isothermal calorimetry to characterise stability of amorphous pharmaceuticals.
• Implement the latest technological developments.
• Discuss the best approaches to control and stabilise amorphous drug forms.
• Examine the quantifi cation of amorphous content.
• Gain a clearer insight on amorphous food materials.
• Seize this opportunity to network with leaders from pharma-biotech, healthcare and regulatory agencies.
Who should attend?
VPs, Directors, Heads and Managers of:
• Stability / Stability testing
• Pre-formulation
• Solid State Chemistry
• Formulation
• Crystallisation • Drug Discovery
• Drug Delivery
• Analytical methods / development
• API Development • Validation
• Pharmacokinetics • Quality Control
• R&D
• Product Submission
• Research and Development • Materials Science
• Technical Operations
• Statistical Sciences
• Manufacturing Science
• Regulatory affairs
• Particle Engineering
• Product Design
• Business Development
Day 1
Amorphous Pharmaceutical Materials,
Monday 24th January 2011, London, UK
09:30 Registration and refreshments,
10:00 Opening address from the chair
10:10 Amorphous content: Quantification in drug substance and drug product.
• Ways to trace amorphous content in crystalline solids.
• Ways to trace amorphous content in formulated products.
• Micronisation and amorphisation.
• Impact on drug substance properties.
Dr Rolf Hilfiker,
Vice President, Head of Department Solid-State Development, Solvias.
10:50 Biopharmaceutical implications for development of amorphous solid solution intermediates.
• Why amorphous solid dispersions / solutions.
• Current in vitro testing strategies.
• Physiology of the gastrointestinal tract and its relevance to oral delivery of poorly soluble compounds.
• Case Study: novel amorphous microparticle technology for targeted drug delivery.
Mark Saunders,
Owner, co-founder and Development Director, Kuecept.
11:30 Morning refreshments
11:50 Approach to amorphous detection and quantitation within GSK,
• Internal strategy, methods and techniques.
• Case study A: detection and quantitation of amorphous for micronised material.
• Case study B: dealing with amorphous formation in a Liquid Deposited Formulation.
Franco Sartor,
Principal scientist, GlaxoSmithKline,
12:30 Amorphous food materials – Some lessons from food research,
• Hot melt extruded flavour encapsulation systems, a vitrified emulsion.
• Small molecules: solvent, plasticiser, both or neither?
• Protein stability in the glass state: physical, chemical and biological.
• Brian Arthur’s “The Nature of Technology”: so what’s new?
Roger Parker,
Senior Scientist, Food Structure and Health Programme, BBSRC Institute of Food Research.
14:30 Stable amorphous dispersions – science, formulation and manufacturing method,
• Methods of manufacture and the importance for stability.
• Relaxation of bulk and surface.
• Intentional and accidental amorphous materials.
• Use of NIR, IGC, and thermal methods.
• The value of Raman mapping.
Prof. Graham Buckton,
Chief Executive Officer, Pharmaterials
15:10 Amorphisation as Tool for Product Life Cycle Management,
• Phases and critical steps in LCM.
• Solid form roles in LCM.
• Activery the amorphisation company.
• Current and future products.
• Amorphous combinations, single drug products and nanoparticles.
Dr. Andreas Kordikowski.
R&D Director, Activery Biotech.
15:30 Afternoon refreshments.
15:50 Patents - amorphous materials & formulations.
• Satisfying patentability requirements.
• Practical advice to drafting strong claims.
• Assessing infringement.
• Reviewing recent case law examples.
Robert Whittock,
IP/IT, Practice Group, Freshfields Bruckhaus Deringer.
16:30 Strategies to protect and commercialise innovations in amorphous materials.
• How to draft for existing active ingredients.
• Create a return on investments and maintain market position.
• Effective enforcement.
Wouter Pors,
Attorney at law, Bird & Bird,
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Amorphous Pharmaceutical Materials
Tuesday 25th January 2011, London, UK
09:30 Registration and refreshments.
10:00 Opening address from the chair.
10:10 Partially amorphous materials: In-situ monitoring of the recrystallisation process at the nanoscale using heated tip AFM.
• Process-induced disorder and its importance in pharmaceutical industry
• The use of Atomic Force Microscopy (AFM) and related techniques for detection and characterisation of process-induced changes in pharmaceutical materials, incl. several examples from the literature.
• Novel Nano-thermal analysis approach to characterisation of partially amorphous materials at the nanoscale, incl. examples of in-situ monitoring of the recrystallisation process.
Ljiljana Harding
Inhalation & Devices Centre of Emphasis, Pfizer.
10:50 Automated solid dispersion screening: A useful tool to design amorphous systems.
• The approach to automate and miniaturize the search for precipitation inhibitors.
• Preparation of amorphous films.
• Evaluation of amorphous systems.
Sigrid Stokbroekx,
Research Fellow, Johnson & Johnson Pharmaceutical R&D.
11:30 Morning refreshments.
11:50 Stability assessment of amorphous pharmaceuticals with calorimetry.
• Instrument considerations and experimental design.
- Scanning calorimetry and isothermal calorimetry.
• Determination of relaxation rates.
• Examples of applications.
- Measurement of glass transitions with DSC.
- Stability of glassy pharmaceuticals.
- Oral fast-dissolving films.
Dr Simon Gaisford,
Senior Lecturer in Pharmaceutics, The School of Pharmacy, University of London.
12:30 Patenting amorphous forms - EPO views.
• What distinguishes amorphous forms from other patentable products?
• How to claim amorphous forms properly?
• How to disclose amorphous forms and support this disclosure properly?
• Case law of interest.
Bertrand Gellie,
Director of Organic Chemistry, European Patent Office.
13:10 Networking lunch.
14:30 Formulating materials to retain amorphous character –ensuring you get what you pay for,
• Amorphous materials are highly active in their nature and need careful processing to ensure they retain their amorphous character.
• Many amorphous materials also have low bulk density and present handling problems.
• Formulation development to ensure the products retain their amorphous character, otherwise the desirable properties will be lost.
• Enabling the small scale manufacture of products containing amorphous materials for use in preclinical and Phase 1 testing while retaining their amorphous character and overcoming bulk density problems.
• Reviewing the possible impact of common pharmaceutical processes on amorphous character.
Michael Gamlen,
Managing Director, Pharmaceutical Development Services.
15:10 Developing solid dispersions by spray drying.
• The role of solid dispersions.
• Methods to produce solids dispersions.
• O Spray drying of solid dispersions.
Dr. Filipe Gaspar
Head of Particle Design, Hovione.
15:40 Afternoon refreshments.
16:10 Process analytical techniques during amorphisation by hot melt extrusion.
• Hot melt extrusion: generation of amorphous and co-crystal forms.
• Process Analytical Technique (PAT) in melt extrusion: Online rheology and NIR measurement.
Prof. Anant Paradkar PhD.
Professor of Pharmaceutical Engineering, Interdisciplinary Chair in Pharmaceutical Engineering Science, University of Bradford.
16:50 Chair’s closing remarks.
17:00 End of Conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=132812&rt=Conference-on-Amorphous-Pharmaceutical-Materials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Assessing emerging applications, methodologies, techniques and challenges.
24th - 25th January 2011, BSG Conference Centre, London, UK
Key Speakers:
Ljiljana Harding, Inhalation & Devices Centre of Emphasis, Pfizer,
Franco Sartor, Principal scientist , GlaxoSmithKline,
Sigrid Stokbroekx, Research Fellow, Johnson & Johnson Pharmaceutical R&D,
Dr. Rolf Hilfiker, Vice President Head of Department Solid-State Development, Solvias,
Roger Parker, Senior Scientist, Food Structure and Health Programme, Institute of Food Research,
Dr. Simon Gaisford, Senior Lecturer in Pharmaceutics, The School of Pharmacy, University of London
Mark Saunders, Owner, co-founder and Development Director, Kuecept,
Robert Whittock, IP/IT Practice Group, Freshfields Bruckhaus Deringer LLP,
Wouter Pors, Attorney, Bird & Bird,
Michael Gamlen, Managing Director, Pharmaceutical Development Services,
Prof. Graham Buckton, Chief Executive Officer, Pharmaterials,
Dr. Andreas Kordikowski, R&D Director, Activery Biotech,
Dr. Filipe Gaspar, Head of Particle Design, Hovione
Bertrand Gellie, Director of Organic Chemistry, European Patent Office.
Conference Introduction,
Amorphous Pharmaceutical Materials,
24th - 25th January 2011, London, UK.
With the continuous increase in the number of insoluble developmental drug molecules and growing regulatory scrutiny over pharmaceutical solids, the use of amorphous solids is steadily rising in the pharmaceutical companies. This conference combines presentations on the approaches to amorphous detection and quantitation within GSK, and clinical advice and practical tips from Pfizer and Johnson & Johnson. The biopharmaceutical implications for development of amorphous solid solution intermediates will be discussed and strategies to protect and commercialise innovations in amorphous materials will be presented.During the two days you will be exposed to several analytical strategies to protect and commercialise innovations in amorphous materials. Amorphous Pharmaceutical conference will provide an enlightening and thought-provoking forum with a series of case studies ranging from amorphous formulation to novel amorphous microparticle technology.
Reasons to register today:
• Understand the use of isothermal calorimetry to characterise stability of amorphous pharmaceuticals.
• Implement the latest technological developments.
• Discuss the best approaches to control and stabilise amorphous drug forms.
• Examine the quantifi cation of amorphous content.
• Gain a clearer insight on amorphous food materials.
• Seize this opportunity to network with leaders from pharma-biotech, healthcare and regulatory agencies.
Who should attend?
VPs, Directors, Heads and Managers of:
• Stability / Stability testing
• Pre-formulation
• Solid State Chemistry
• Formulation
• Crystallisation • Drug Discovery
• Drug Delivery
• Analytical methods / development
• API Development • Validation
• Pharmacokinetics • Quality Control
• R&D
• Product Submission
• Research and Development • Materials Science
• Technical Operations
• Statistical Sciences
• Manufacturing Science
• Regulatory affairs
• Particle Engineering
• Product Design
• Business Development
Day 1
Amorphous Pharmaceutical Materials,
Monday 24th January 2011, London, UK
09:30 Registration and refreshments,
10:00 Opening address from the chair
10:10 Amorphous content: Quantification in drug substance and drug product.
• Ways to trace amorphous content in crystalline solids.
• Ways to trace amorphous content in formulated products.
• Micronisation and amorphisation.
• Impact on drug substance properties.
Dr Rolf Hilfiker,
Vice President, Head of Department Solid-State Development, Solvias.
10:50 Biopharmaceutical implications for development of amorphous solid solution intermediates.
• Why amorphous solid dispersions / solutions.
• Current in vitro testing strategies.
• Physiology of the gastrointestinal tract and its relevance to oral delivery of poorly soluble compounds.
• Case Study: novel amorphous microparticle technology for targeted drug delivery.
Mark Saunders,
Owner, co-founder and Development Director, Kuecept.
11:30 Morning refreshments
11:50 Approach to amorphous detection and quantitation within GSK,
• Internal strategy, methods and techniques.
• Case study A: detection and quantitation of amorphous for micronised material.
• Case study B: dealing with amorphous formation in a Liquid Deposited Formulation.
Franco Sartor,
Principal scientist, GlaxoSmithKline,
12:30 Amorphous food materials – Some lessons from food research,
• Hot melt extruded flavour encapsulation systems, a vitrified emulsion.
• Small molecules: solvent, plasticiser, both or neither?
• Protein stability in the glass state: physical, chemical and biological.
• Brian Arthur’s “The Nature of Technology”: so what’s new?
Roger Parker,
Senior Scientist, Food Structure and Health Programme, BBSRC Institute of Food Research.
14:30 Stable amorphous dispersions – science, formulation and manufacturing method,
• Methods of manufacture and the importance for stability.
• Relaxation of bulk and surface.
• Intentional and accidental amorphous materials.
• Use of NIR, IGC, and thermal methods.
• The value of Raman mapping.
Prof. Graham Buckton,
Chief Executive Officer, Pharmaterials
15:10 Amorphisation as Tool for Product Life Cycle Management,
• Phases and critical steps in LCM.
• Solid form roles in LCM.
• Activery the amorphisation company.
• Current and future products.
• Amorphous combinations, single drug products and nanoparticles.
Dr. Andreas Kordikowski.
R&D Director, Activery Biotech.
15:30 Afternoon refreshments.
15:50 Patents - amorphous materials & formulations.
• Satisfying patentability requirements.
• Practical advice to drafting strong claims.
• Assessing infringement.
• Reviewing recent case law examples.
Robert Whittock,
IP/IT, Practice Group, Freshfields Bruckhaus Deringer.
16:30 Strategies to protect and commercialise innovations in amorphous materials.
• How to draft for existing active ingredients.
• Create a return on investments and maintain market position.
• Effective enforcement.
Wouter Pors,
Attorney at law, Bird & Bird,
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Amorphous Pharmaceutical Materials
Tuesday 25th January 2011, London, UK
09:30 Registration and refreshments.
10:00 Opening address from the chair.
10:10 Partially amorphous materials: In-situ monitoring of the recrystallisation process at the nanoscale using heated tip AFM.
• Process-induced disorder and its importance in pharmaceutical industry
• The use of Atomic Force Microscopy (AFM) and related techniques for detection and characterisation of process-induced changes in pharmaceutical materials, incl. several examples from the literature.
• Novel Nano-thermal analysis approach to characterisation of partially amorphous materials at the nanoscale, incl. examples of in-situ monitoring of the recrystallisation process.
Ljiljana Harding
Inhalation & Devices Centre of Emphasis, Pfizer.
10:50 Automated solid dispersion screening: A useful tool to design amorphous systems.
• The approach to automate and miniaturize the search for precipitation inhibitors.
• Preparation of amorphous films.
• Evaluation of amorphous systems.
Sigrid Stokbroekx,
Research Fellow, Johnson & Johnson Pharmaceutical R&D.
11:30 Morning refreshments.
11:50 Stability assessment of amorphous pharmaceuticals with calorimetry.
• Instrument considerations and experimental design.
- Scanning calorimetry and isothermal calorimetry.
• Determination of relaxation rates.
• Examples of applications.
- Measurement of glass transitions with DSC.
- Stability of glassy pharmaceuticals.
- Oral fast-dissolving films.
Dr Simon Gaisford,
Senior Lecturer in Pharmaceutics, The School of Pharmacy, University of London.
12:30 Patenting amorphous forms - EPO views.
• What distinguishes amorphous forms from other patentable products?
• How to claim amorphous forms properly?
• How to disclose amorphous forms and support this disclosure properly?
• Case law of interest.
Bertrand Gellie,
Director of Organic Chemistry, European Patent Office.
13:10 Networking lunch.
14:30 Formulating materials to retain amorphous character –ensuring you get what you pay for,
• Amorphous materials are highly active in their nature and need careful processing to ensure they retain their amorphous character.
• Many amorphous materials also have low bulk density and present handling problems.
• Formulation development to ensure the products retain their amorphous character, otherwise the desirable properties will be lost.
• Enabling the small scale manufacture of products containing amorphous materials for use in preclinical and Phase 1 testing while retaining their amorphous character and overcoming bulk density problems.
• Reviewing the possible impact of common pharmaceutical processes on amorphous character.
Michael Gamlen,
Managing Director, Pharmaceutical Development Services.
15:10 Developing solid dispersions by spray drying.
• The role of solid dispersions.
• Methods to produce solids dispersions.
• O Spray drying of solid dispersions.
Dr. Filipe Gaspar
Head of Particle Design, Hovione.
15:40 Afternoon refreshments.
16:10 Process analytical techniques during amorphisation by hot melt extrusion.
• Hot melt extrusion: generation of amorphous and co-crystal forms.
• Process Analytical Technique (PAT) in melt extrusion: Online rheology and NIR measurement.
Prof. Anant Paradkar PhD.
Professor of Pharmaceutical Engineering, Interdisciplinary Chair in Pharmaceutical Engineering Science, University of Bradford.
16:50 Chair’s closing remarks.
17:00 End of Conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=132812&rt=Conference-on-Amorphous-Pharmaceutical-Materials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on Phase I Clinical Trials Summit
Conference on Phase I Clinical Trials Summit
Strategies for improving Phase I trial design, management and execution
To be held at 28th – 29th October 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Eckhard von Keutz, Senior Vice President Head Global Early Development, Bayer Schering Pharma
Dr. Walter Janssens Coordinator Early Phase Development, FAGG/AFMPS
Corina Dota ECG Centre Manager, Medical Science Sweden, AstraZeneca
Dr. Fatiha Sadallah, Principal Scientifi c Manager, Innovative Medicines Initiative (IMI)
Dr. Andrea Laslop, Head of Institute Science and Information, AGES PharmMed
Rob Nichols, Director of Commercial Development, Phase Forward Europe
Dr. Finbarr Cotter Prof of Haematology, Medical Oncology, Barts and the London School of Medicine
Robert Blakie, Director, ERA Consulting
Dr. Assem S. el Baghdady, Director, Alpha Beta Pharma
Dr. Jennifer J. Wheler, Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center
Professor Atholl Johnston, Professor of Clinical Pharmacology, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London
Dr. Dominic Williams, MRC Centre for Drug Safety Science, The University of Liverpool
Who should attend?
Vice/Presidents, Directors, Heads of:
• Clinical Operations • Clinical Research
• Clinical Development
• Exploratory Development
• Strategic Drug Development
• Clinical Trial Design
• Clinical Pharmacology / Pharmacometrics
• Quality Assurance / Quality Control • Pharmacokinetics/ Pharmacodynamics
• Project Management
• Regulatory Affairs
• Scientifi c Relations
• Statistical Methodology
Day 1
Phase I Clinical Trials Summit
Thursday 28th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 The use of biomarkers early in clinical development
• Biomarkers as go/no-go in early clinical development
• Do biomarkers worth the cost or the time?
• Can we use biomarkers in late clinical development too?
• What role do biomarkers play in the clinic?
Dr. Assem S. el Baghdady
Director, Alpha Beta Pharma
Formerly Medical Director R&D, Norgine
10:20 Exploring translatability from phase I to phase IIb
• Clarify different concepts of biomarkers
• Speed up the transition from Phase I to Phase IIb
• Integrative assessment of available data
• Designing biomarker studies efficiently for informative decision making in clinical development
• Illustrative example in diabetes
Dr. Arne Ring
Team Leader Biostatistics Phase I/IIa
Boehringer Ingelheim Pharma
11:00 Morning refreshments
11:20 Regulatory experience with exploratory clinical trials
• Critical issues in the trial application
- preclinical
- quality issues
- protocol related
• Experience in Belgium with exploratory clinical trials
Dr. Walter Janssens
Coordinator Early Phase Development
FAGG/AFMPS
12:00 Phase I clinical trials: beside to bench
Dr. Jennifer J. Wheler
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
12:40 Networking lunch
13:40 Reducing the cost of clinical QT studies
• Relationship between the electrocardiographic precision and the study size
• Electrocardiographic methods to increase measurement precision
• Design implications for crossover and parallel studies
• Advantages of continuous ECG acquisition
• Optimum combinations of computerised and manual readings to reduce the cost of ECG analysis
Marek Malik
Professor of Cardiac Electrophysiology, Head, Noninvasive Electrocardiology
St. George’s, University of London
14:20 Evaluating the efficiency of design methods and implementing early clinical trials with novel therapeutics
• Determine dose and schedule
• Discuss continual reassessment methods
• Study specific target patient populations
15:00 Afternoon refreshments
15:20 Study design for Leukaemia therapy
• What does we mean by Phase I studies in the context of Leukaemia
• What are the goals
• How do we design the study
• How to we record and evaluate the trial
• What are added value studies
Dr. Finbarr Cotter
Prof of Haematology, Medical Oncology
Barts and the London School of Medicine
16:00 Update on ICH guidelines
• Review the guidelines
• Discuss the risk benefit
• Examine the regulatory requirements
16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Phase I Clinical Trials Summit
Friday 29th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Preparing phase I clinical trials
• Early clinical trials methodology
• Principles of laboratory methodologies
• Reviewing preclinical data
Professor Atholl Johnston
Professor of Clinical Pharmacology, Barts and the London
School of Medicine and Dentistry
Queen Mary University of London
10:20 Understanding the importance of preclinical
studies for clinical success
• What has changed?
• What is necessary?
• Opportunities for better investigations
• Opportunities for cross-functional cooperation
Dr. Eckhard von Keutz
Senior Vice President, Head, Global Early Development
Bayer Schering Pharma
11:00 Morning refreshments
11:20 Clinical trials data management in phase I
12:00 The case for automating phase I clinical trials
• Understand the unique challenges for phase I clinical units and how these can be addressed by improved use of automated
solutions
• Appreciate the breadth of available solutions suitable for phase I
• Understand the key issue areas to consider when planning a
smooth implementation
Rob Nichols
Director, Commercial Development
Phase Forward Europe
12:40 Networking lunch
13:40 Translational medicine in Europe: Role of the innovative medicines initiative :IMI
• Public-private partnership in the health sector
• Building on strengths and tackling weaknesses in the EU
• IMI first two calls for proposals
Dr. Fatiha Sadallah
Principal Scientific Manager
Innovative Medicines Initiative (IMI)
14:20 Presentation to be announced
Dr. Andrea Laslop
Head of Institute Science and Information
AGES PharmMed
15:00 Afternoon refreshments
15:20 Cardiovascular risk profiling in early clinical development
• Role of preclinical testing for cardiovascular safety profiling
• What can be achieved in the early phase 1 studies?
• What are the technologies at hand to ensure quality and cost efficiencies in early clinical development
Corina Dota
ECG Centre Manager, Medical Science Sweden
AstraZeneca
16.00 Mechanism-based markers of murine drug-induced liver injury
• Paracetamol as a tool for translational hepatotoxicity
• Use of keratin-18 as a serum marker of apoptosis
• Use of High Mobility Group box-1 as a serum marker of necrosis
• Fed and fasted animal models in pre-clinical development
Dr. Dominic Williams
MRC Centre for Drug Safety Science, Dept.
Pharmacology & Therapeutics
The University of Liverpool
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=136318&rt=Conference-on-Phase-I-Clinical-Trials-Summit.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Strategies for improving Phase I trial design, management and execution
To be held at 28th – 29th October 2010, BSG Conference Centre, London, UK
Key Speakers
Dr. Eckhard von Keutz, Senior Vice President Head Global Early Development, Bayer Schering Pharma
Dr. Walter Janssens Coordinator Early Phase Development, FAGG/AFMPS
Corina Dota ECG Centre Manager, Medical Science Sweden, AstraZeneca
Dr. Fatiha Sadallah, Principal Scientifi c Manager, Innovative Medicines Initiative (IMI)
Dr. Andrea Laslop, Head of Institute Science and Information, AGES PharmMed
Rob Nichols, Director of Commercial Development, Phase Forward Europe
Dr. Finbarr Cotter Prof of Haematology, Medical Oncology, Barts and the London School of Medicine
Robert Blakie, Director, ERA Consulting
Dr. Assem S. el Baghdady, Director, Alpha Beta Pharma
Dr. Jennifer J. Wheler, Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas M. D. Anderson Cancer Center
Professor Atholl Johnston, Professor of Clinical Pharmacology, Barts and the London School of Medicine and
Dentistry, Queen Mary University of London
Dr. Dominic Williams, MRC Centre for Drug Safety Science, The University of Liverpool
Who should attend?
Vice/Presidents, Directors, Heads of:
• Clinical Operations • Clinical Research
• Clinical Development
• Exploratory Development
• Strategic Drug Development
• Clinical Trial Design
• Clinical Pharmacology / Pharmacometrics
• Quality Assurance / Quality Control • Pharmacokinetics/ Pharmacodynamics
• Project Management
• Regulatory Affairs
• Scientifi c Relations
• Statistical Methodology
Day 1
Phase I Clinical Trials Summit
Thursday 28th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 The use of biomarkers early in clinical development
• Biomarkers as go/no-go in early clinical development
• Do biomarkers worth the cost or the time?
• Can we use biomarkers in late clinical development too?
• What role do biomarkers play in the clinic?
Dr. Assem S. el Baghdady
Director, Alpha Beta Pharma
Formerly Medical Director R&D, Norgine
10:20 Exploring translatability from phase I to phase IIb
• Clarify different concepts of biomarkers
• Speed up the transition from Phase I to Phase IIb
• Integrative assessment of available data
• Designing biomarker studies efficiently for informative decision making in clinical development
• Illustrative example in diabetes
Dr. Arne Ring
Team Leader Biostatistics Phase I/IIa
Boehringer Ingelheim Pharma
11:00 Morning refreshments
11:20 Regulatory experience with exploratory clinical trials
• Critical issues in the trial application
- preclinical
- quality issues
- protocol related
• Experience in Belgium with exploratory clinical trials
Dr. Walter Janssens
Coordinator Early Phase Development
FAGG/AFMPS
12:00 Phase I clinical trials: beside to bench
Dr. Jennifer J. Wheler
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
12:40 Networking lunch
13:40 Reducing the cost of clinical QT studies
• Relationship between the electrocardiographic precision and the study size
• Electrocardiographic methods to increase measurement precision
• Design implications for crossover and parallel studies
• Advantages of continuous ECG acquisition
• Optimum combinations of computerised and manual readings to reduce the cost of ECG analysis
Marek Malik
Professor of Cardiac Electrophysiology, Head, Noninvasive Electrocardiology
St. George’s, University of London
14:20 Evaluating the efficiency of design methods and implementing early clinical trials with novel therapeutics
• Determine dose and schedule
• Discuss continual reassessment methods
• Study specific target patient populations
15:00 Afternoon refreshments
15:20 Study design for Leukaemia therapy
• What does we mean by Phase I studies in the context of Leukaemia
• What are the goals
• How do we design the study
• How to we record and evaluate the trial
• What are added value studies
Dr. Finbarr Cotter
Prof of Haematology, Medical Oncology
Barts and the London School of Medicine
16:00 Update on ICH guidelines
• Review the guidelines
• Discuss the risk benefit
• Examine the regulatory requirements
16:40 Closing remarks from the chair
16:50 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
Phase I Clinical Trials Summit
Friday 29th October 2010
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Preparing phase I clinical trials
• Early clinical trials methodology
• Principles of laboratory methodologies
• Reviewing preclinical data
Professor Atholl Johnston
Professor of Clinical Pharmacology, Barts and the London
School of Medicine and Dentistry
Queen Mary University of London
10:20 Understanding the importance of preclinical
studies for clinical success
• What has changed?
• What is necessary?
• Opportunities for better investigations
• Opportunities for cross-functional cooperation
Dr. Eckhard von Keutz
Senior Vice President, Head, Global Early Development
Bayer Schering Pharma
11:00 Morning refreshments
11:20 Clinical trials data management in phase I
12:00 The case for automating phase I clinical trials
• Understand the unique challenges for phase I clinical units and how these can be addressed by improved use of automated
solutions
• Appreciate the breadth of available solutions suitable for phase I
• Understand the key issue areas to consider when planning a
smooth implementation
Rob Nichols
Director, Commercial Development
Phase Forward Europe
12:40 Networking lunch
13:40 Translational medicine in Europe: Role of the innovative medicines initiative :IMI
• Public-private partnership in the health sector
• Building on strengths and tackling weaknesses in the EU
• IMI first two calls for proposals
Dr. Fatiha Sadallah
Principal Scientific Manager
Innovative Medicines Initiative (IMI)
14:20 Presentation to be announced
Dr. Andrea Laslop
Head of Institute Science and Information
AGES PharmMed
15:00 Afternoon refreshments
15:20 Cardiovascular risk profiling in early clinical development
• Role of preclinical testing for cardiovascular safety profiling
• What can be achieved in the early phase 1 studies?
• What are the technologies at hand to ensure quality and cost efficiencies in early clinical development
Corina Dota
ECG Centre Manager, Medical Science Sweden
AstraZeneca
16.00 Mechanism-based markers of murine drug-induced liver injury
• Paracetamol as a tool for translational hepatotoxicity
• Use of keratin-18 as a serum marker of apoptosis
• Use of High Mobility Group box-1 as a serum marker of necrosis
• Fed and fasted animal models in pre-clinical development
Dr. Dominic Williams
MRC Centre for Drug Safety Science, Dept.
Pharmacology & Therapeutics
The University of Liverpool
16:40 Chair’s closing remarks
16:50 End of conference
For more information visit
http://www.bharatbook.com/detail.asp?id=136318&rt=Conference-on-Phase-I-Clinical-Trials-Summit.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on 7th Annual Pain Management
Conference on 7th Annual Pain Management
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK
Background Info
Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?
Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.
Learn, exchange ideas and acquire knowledge on:
• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies
Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine
Day 1
7th Annual Pain Management
Monday 18th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the chair.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.
Anastasia Liapi
Director, Business Development Astellas
10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.
Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University
11:30 Morning refreshments.
11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.
Iain Chessell
Vice President, Neuroscience MedImmune
12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.
Steve England
Associate Research Fellow Pfizer
13:10 Networking lunch.
14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.
Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University
14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
15:30 Afternoon refreshments.
15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.
16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
7th Annual Pain Management
Tuesday 19th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the Chair.
Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer
10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.
Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson
10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.
Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester
11:30 Morning refreshments.
11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.
Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital
12:30 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford
13:10 Networking lunch.
14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.
Stephen Wright
Research and Development Director GW Pharmaceuticals
Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen
14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?
15:30 Afternoon refreshments.
15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.
Dic Williams
Research Fellow, Pain Therapeutics Pfizer
16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.
17:10 Chair’s closing remarks.
17:20 End of conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Accelerating innovation in drugs and devices for successful pain management
18th – 19th October 2010, BSG House, London, UK
Background Info
Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?
Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.
Learn, exchange ideas and acquire knowledge on:
• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies
Who should attend?
Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine
Day 1
7th Annual Pain Management
Monday 18th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the chair.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
10:10 A world of pain: Current and future market dynamics.
• Market dynamics in key pain indications and emerging trends.
• Changes in industrial landscape during the last year: Who is still standing and new kids on the block?
• Commercial considerations during drug development: R&D with the end in mind.
Anastasia Liapi
Director, Business Development Astellas
10:50 Developing a two step approach for treating diabetic neuropathy: Eliminating the cause and relieving the symptoms.
• Management of symptomatic diabetic sensory neuropathy: A therapeutic challenge.
• Using Aanticonvulsant and antiarrhythmic agents, and opioid-like medications.
• Topical therapies and non pharmalogic approaches.
• Recent advances in the diagnosis and management of diabetic neuropathy.
Dr James Campbell
CEO, Arcion Therapeutics
Professor, Department of Neurosurgery, School of Medicine Johns Hopkins University
11:30 Morning refreshments.
11:50 The use of biologic therapies for pain management: The next revolution?
• Review on how biologic therapies accelerate pain management: An analysis of preliminary data.
• Evaluating mAbs over traditional therapies: Target engagement, on- versus off-target tolerability profiles and potency/affinity.
• Examining the pros and cons of biologic therapies for pain.
• Current and future directions in pain management through biologic therapies.
Iain Chessell
Vice President, Neuroscience MedImmune
12:30 Voltage-gated sodium channels in neuropathic pain.
• What happens to sodium channels following peripheral nerve damage?
• What do the preclinical models tell us?
• If we find the right sodium channel modulator, will it work in the clinic?
• Future perspectives.
Steve England
Associate Research Fellow Pfizer
13:10 Networking lunch.
14:10 Evaluating analgesic effect in experimental visceral pain models through translational pain research.
• Assessing the challenges in pathophysiology of deep visceral pain.
• Optimising treatment and improving knowledge of the mechanisms and mode of action of analgesic substances.
• Experimental human visceral pain research for evaluation of analgesic action.
• Bridging the gap for translational pain research.
Anne Estrup Olesen
Mech-Sense, Department of Gastroenterology Aalborg University
14:50 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium, University of Oxford
15:30 Afternoon refreshments.
15.50 NSAIDs for Pain management: Safety and efficacy of NSAIDs.
NSAIDs are among the most common pain relievers in the world. And lately, they’re among the most controversial. Through this panel a discussion we will discuss the benefits and risks of NSAIDs.
16:30 Exploiting cannabinoids for pain relief: Current and emerging pharmacological strategies.
• Current strategy for targeting cannabinoid receptors.
• Emerging strategies for targeting cannabinoid receptors.
• Results from clinical trials.
17:10 Closing remarks from the chair.
17:20 Networking drinks.
Take your discussions further and build new relationships in a relaxed and informal setting.
Day 2
7th Annual Pain Management
Tuesday 19th October 2010
09:30 Registration and refreshments.
10:00 Opening address from the Chair.
Dr Dic Williams
Research Fellow, Pain Therapeutics Pfizer
10:10 Development of treatments for peripheral neuropathies.
• Existing treatment options.
• Preclinical research.
• Growth factors.
• POC modeling in humans.
Theo F Meert
Professor, Katholieke Universiteit Leuven and University of Antwerp
Senior Research Fellow, Neuroscience Johnson and Johnson
10:50 Human experimental pain models in early drug development.
• Translation from animal to human pain models.
• Back-translation from human models to animal models.
• Translating from human experimental pain models in volunteers to pain patients.
• Mechanisms based proof-of-concept studies.
• The concept of multi-model, multi-tissue pain models.
• Integrating pain models in phase Ib studies.
Prof Anthony Jones
Professor of Neuro-rheumatology,
Human Pain Research Group University of Manchester
11:30 Morning refreshments.
11:50 Advancements and emerging therapies for neuropathic pain.
• Emerging therapies for neuropathic pain.
• Current challenges: High unmet medical needs for new treatments with better efficacy and improved tolerability.
• Investigation of novel targets.
Jonathan Stewart
Honorary Consultant, Pain Medicine St Mary’s Hospital
12:30 What is the impact of chromatin modifications on establishing chronic pain state?
• Role of early life experiences.
• Can these changes be modulated to deliver new therapies?
• Will they be superior targets for drug discovery?
• Potential targets.
Chas Bountra
Chief Scientist, Structural Genomics Consortium University of Oxford
13:10 Networking lunch.
14:10 Cannabinoids and opioids: Case for synergy.
• Pharmacologic basis for a positive interaction.
• Animal studies.
• Clinical study concept validation.
Stephen Wright
Research and Development Director GW Pharmaceuticals
Prof Roger Pertwee
Professor of Neuropharmacology University of Aberdeen
14:50 Development of novel NSAIDs and COX-2 inhibitors in the post-Vioxx era.
• What have we learned about GI and cardiovascular risk?
• What strategies are being employed to improve GI and cardiovascular safety?
- Example #1: Naproxcinod, a nitric-oxide donating analog of naproxen.
- Example #2: CG100649, a dual inhibitor of COX-2 and carbonic anhydrase.
• Are regulatory hurdles manageable in the USA and Europe?
15:30 Afternoon refreshments.
15.50 Future pain management: emerging new mechanisms and modalities.
• Overview of the established pain relief mechanisms: Non-steroidal anti-inflammatory and opiates.
• Maximising therapeutic benefit and efficacy of pain relief mechanisms.
- Development of innovative formulation.
- Alternative routes of administration.
- Use of combination products to reduce safety risks.
• Approaches to novel mechanisms to fulfil unmet needs.
• Driving renewed investment in novel target space and emergence of novel treatment modalities.
Dic Williams
Research Fellow, Pain Therapeutics Pfizer
16:30 Spinal cord stimulation for chronic pain.
• Spinal cord stimulation (SCS): An evidence-based therapy for the management of persisting pain.
• Review on the efficacy and effectiveness of spinal cord stimulation in relieving certain kinds of pain.
• Good indications for SCS.
17:10 Chair’s closing remarks.
17:20 End of conference.
For more information visit
http://www.bharatbook.com/detail.asp?id=134329&rt=Conference-on-7th-Annual-Pain-Management.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on CNS Clinical Trials
Conference on CNS Clinical Trials
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientifi c Offi cer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Senior Research Fellow - Psychiatric Disorders Drug Hunting Team, Lilly
Dr Simone Braggio, Director Neurosciences CEDD DMPK, GlaxoSmithKline
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience, University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientifi c Offi cer, MS Therapeutics
Nancy Mulligan, VP, CNS / Mental Health, MMG
Professor Mehdi Adineh, Scientifi c Director Diagnostic Imaging Core Laboratory, American College of
Radiology Imaging Network (ACRIN)
CNS is one of the largest and fastest growing therapeutic areas of the
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.
CNS Clinical Trials conference you will examine the strategies offering
the greatest potential for success in CNS drug development, and understand the specifi c
challenges currently faced by developers in this market. In order to enhance productivity
in this fi eld, there has been an increased awareness of the need to align clinical and
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy
in all phases of CNS trials, enabling CNS developers to make more timely decisions.
By attending this conference you will:
• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and
patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical
CNS trials
• Be part of a major networking opportunity
Target Audience:
• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations
Who will be there?
Senior VPs, VPs, Chief Scientifi c Offi cers, Directors, Heads and
Managers of:
• CNS Trials
• Clinical Trials
• Clinical Research & Development
• Clinical Operations
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology
• Neurology/ Neuroscience Research
• Psychiatry
• Psychology
• CNS Ageing Research
• Dementia
• Imaging/ Neuroimaging
• Movement Disorders
• CNS Global Marketing & Medicine
• Preclinical R&D
• Translational Medicine
• Biostatistics
• Experimental Therapeutics
• Clinical Technology
• Outcomes Research
• Regulatory Affairs
• Product Development
Day 1,Monday 16th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 The discovery and development of CNS medicines
• Progress in CNS medicines research
• Market landscape
• The challenges for CNS R&D
• Future prospects
Professor Alan M Palmer
Chief Scientific Officert
MS Therapeutics
10:50 Addressing specific challenges arising in the clinical trials of neuroprotective agents
11:30 Morning refreshments
11:50 Clinical value of accelerated anti-depressant effect
• Lag time of antidepressants: an unmet medical need
• Early and Sustained Full Response: A new FDA approved
efficacy paradigm
• Pharmacological considerations to induce accelerated
antidepressant effect
• Treatment adherence in relation to an antidepressant with an
accelerated effect
Dr Erik Buntinx
Managing Director and Chief Scientific Officer
PharmaNeuroBoost
12:30 Considerations for design and statistical analysis
of CNS trials
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
13:10 Networking Lunch
14:30 mGluR5 Allosteric Antagonists: Preclinical profile and choice of therapeutic indication
• Characterization of mGluR5 antagonist in preclinical paradigm
• Validation of objective markers for monitoring drug action
• Use of preclinical profiling and proof-of-concept clinical trials to
select therapeutic indications for full development
Dr Fabrizio Gasparini
Sr Research Investigator Novartis Institutes for BioMedical Research
15:10 Suicidality: Ensuring quality in mandated prospective monitoring
• Overview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
• Potential pitfalls with collection of suicidality monitoring data
• eC-SSRS - electronically modeling and reproducing the optimal
human interview
• eC-SSRS – meeting the goals of excellent science and clinical care
• eC-SSRS – a clinical trial case study
Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health
15:50 Afternoon refreshments
16:10 CNS clinical trials beyond registration
• Trials beyond registration a tool for assessing a drug in real-life setting
• Types of post-registration studies, goals, deliverables and methods
• When should trials beyond registration begin?
• Life cycle management and drug safety- 2 sides for the same coin
• Who initiates investigator-initiated-trials and what is their purpose
Dr Samuel Agus
Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
16:50 Closing remarks from the chair
Day2,Thursday 17th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Bridging the gap between pre-clinical and
clinical CNS trials
• Translational assays of cognition
• Animal models of cognitive impairment
• Use of preclinical biomarkers to enhance assay translation
• Clinical testing of preclinical hypotheses
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience
Eli Lilly and Co
10:50 Reducing the gap between preclinical PK/PD and CNS clinical trials
• Adding value to the discovery of CNS active drugs through the application of mechanistic PK/PD principles
• Understanding the key drivers of in-vivo pharmacological effects and ensuring they are prominent in the lead optimisation paradigm
• Establishing the link between blood concentration, receptor occupancy and drug efficacy
11:30 Morning refreshments
11:50 Novel imaging approaches in clinical trials and the role of an imaging CRO
• Novel Imaging Approaches including Structural, Functional and Molecular in CNS Drug Discovery including PET, DTI, fMRI and vCT.
• Imaging Drug Actions Including Neuroreceptor Mapping
• The role of an Imaging CRO in Managing an Imaging Clinical Trial
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory
American College of Radiology
12:30 Utilising PET imaging biomarkers
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues
• Parkinson’s disease: dopamine synthesis & storage capacity
• Psychiatric disorders: dopamine & serotonin receptor occupancy
• Brain tumours: progression and infiltration
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
University of Manchester
13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
Dr. Michael G. Palfreyman
Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
14:50 Recruiting strategies for Huntington’s Disease
clinical trials
• The importance of identifying unique barriers to participation in HD clinical trials
• Grass-roots social marketing for HD trials can speed enrollment:
a pilot study
• Treating the HD trial participant as VIP is a cost-effective approach.
Dr LaVonne Veatch Goodman
Co-founder
Huntington’s Disease Drug Works (HDDW)
15:30 Afternoon refreshments
15:50 Patient recruitment and retention strategies for
CNS clinical trials
• Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
• Strategies for overcoming global CNS patient recruitment challenges
• Updates on evolving trends in patient recruitment and retention methodologies
• Illustrative case studies of effective tactics
Gaynor Anders
Vice President Global Operations
MMG
16.30 Successful strategies for accelerating
patient recruitment
• Preparing for successful enrolment
• The ideal set-up
• Avoiding the pitfalls for a pharma-driven trial
• Enlisting support from patients
Professor Elaine Rankin
Medical Oncology
University of Dundee
17:10 Chair’s closing remarks
17:20 End of conference
Related Reports:
Clinical Trials Market India
Clinical Trials: World Market 2009-2024
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
Trends in Clinical Trials Strategies to enhance clinical trial design
Medical Device Clinical Trials Destination India
For more information visit
http://www.bharatbook.com/detail.asp?id=128073&rt=Conference-on-CNS-Clinical-Trials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Optimising development, management and recruitment for clinical trials in CNS
16th - 17th September 2010, BSG Conference Centre, London, UK
Background Info
Key Speakers
Dr Erik Buntinx, Managing Director and Chief Scientifi c Offi cer, PharmaNeuroBoost
Dr Samuel Agus, Global Medical Affairs Director, Neurology, Solvay Pharmaceuticals Marketing and Licensing
Dr Stig Johan Wiklund, Statistical Science Director, AstraZeneca R&D
Dr Fabrizio Gasparini, Sr Research Investigator, Novartis Institutes for BioMedical Research
Dr Mark Tricklebank Director, Senior Research Fellow - Psychiatric Disorders Drug Hunting Team, Lilly
Dr Simone Braggio, Director Neurosciences CEDD DMPK, GlaxoSmithKline
Dr Karl Herholz Director, Wolfson Molecular Imaging Centre/ Professor of Clinical Neuroscience, University of Manchester
Professor Elaine Rankin, Medical Oncology, University of Dundee
Professor Alan M Palmer, Chief Scientifi c Offi cer, MS Therapeutics
Nancy Mulligan, VP, CNS / Mental Health, MMG
Professor Mehdi Adineh, Scientifi c Director Diagnostic Imaging Core Laboratory, American College of
Radiology Imaging Network (ACRIN)
CNS is one of the largest and fastest growing therapeutic areas of the
pharmaceutical market. The ageing of the baby-boom generation combined
with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.
CNS Clinical Trials conference you will examine the strategies offering
the greatest potential for success in CNS drug development, and understand the specifi c
challenges currently faced by developers in this market. In order to enhance productivity
in this fi eld, there has been an increased awareness of the need to align clinical and
preclinical research to facilitate rapid development of new CNS drug therapies. Medical
imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy
in all phases of CNS trials, enabling CNS developers to make more timely decisions.
By attending this conference you will:
• Examine novel approaches for assessing cognitive function
• Explore the latest advances in neuroimaging
• Develop effective methods for improved patient recruitment and retention
• Understand statistical thinking for designing adaptive trials
• Review Good Clinical Practice GCP guidelines
• Address the regulatory challenges for CNS drug approval
• Utilise biomarkers for Proof of Concept in CNS clinical trials
• Improve trial outcomes through increased communication, ethical consent and
patient care
• Implement translational methods to bridge the gap between pre-clinical and clinical
CNS trials
• Be part of a major networking opportunity
Target Audience:
• Pharmaceutical and biotech companies
• Clinical research organisations
• Regulatory agencies/ associations
Who will be there?
Senior VPs, VPs, Chief Scientifi c Offi cers, Directors, Heads and
Managers of:
• CNS Trials
• Clinical Trials
• Clinical Research & Development
• Clinical Operations
• CNS
• CNS Clinical Biomarker Group
• Clinical Pharmacology
• Neurobiology
• Neuromedical Oncology
• Neurology/ Neuroscience Research
• Psychiatry
• Psychology
• CNS Ageing Research
• Dementia
• Imaging/ Neuroimaging
• Movement Disorders
• CNS Global Marketing & Medicine
• Preclinical R&D
• Translational Medicine
• Biostatistics
• Experimental Therapeutics
• Clinical Technology
• Outcomes Research
• Regulatory Affairs
• Product Development
Day 1,Monday 16th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 The discovery and development of CNS medicines
• Progress in CNS medicines research
• Market landscape
• The challenges for CNS R&D
• Future prospects
Professor Alan M Palmer
Chief Scientific Officert
MS Therapeutics
10:50 Addressing specific challenges arising in the clinical trials of neuroprotective agents
11:30 Morning refreshments
11:50 Clinical value of accelerated anti-depressant effect
• Lag time of antidepressants: an unmet medical need
• Early and Sustained Full Response: A new FDA approved
efficacy paradigm
• Pharmacological considerations to induce accelerated
antidepressant effect
• Treatment adherence in relation to an antidepressant with an
accelerated effect
Dr Erik Buntinx
Managing Director and Chief Scientific Officer
PharmaNeuroBoost
12:30 Considerations for design and statistical analysis
of CNS trials
• Analysis and design for disease modification
• Missing data issues
• Adaptive design issues when applied in CNS trials
Dr Stig Johan Wiklund
Statistical Science Director
AstraZeneca R&D
13:10 Networking Lunch
14:30 mGluR5 Allosteric Antagonists: Preclinical profile and choice of therapeutic indication
• Characterization of mGluR5 antagonist in preclinical paradigm
• Validation of objective markers for monitoring drug action
• Use of preclinical profiling and proof-of-concept clinical trials to
select therapeutic indications for full development
Dr Fabrizio Gasparini
Sr Research Investigator Novartis Institutes for BioMedical Research
15:10 Suicidality: Ensuring quality in mandated prospective monitoring
• Overview of the Columbia-Suicide Severity Rating Scale (C-SSRS)
• Potential pitfalls with collection of suicidality monitoring data
• eC-SSRS - electronically modeling and reproducing the optimal
human interview
• eC-SSRS – meeting the goals of excellent science and clinical care
• eC-SSRS – a clinical trial case study
Dr John Greist
Distinguished Senior Scientist, Madison Institute of Medicine
Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health
15:50 Afternoon refreshments
16:10 CNS clinical trials beyond registration
• Trials beyond registration a tool for assessing a drug in real-life setting
• Types of post-registration studies, goals, deliverables and methods
• When should trials beyond registration begin?
• Life cycle management and drug safety- 2 sides for the same coin
• Who initiates investigator-initiated-trials and what is their purpose
Dr Samuel Agus
Global Medical Affairs Director, Neurology
Solvay Pharmaceuticals Marketing and Licensing
16:50 Closing remarks from the chair
Day2,Thursday 17th March 2010, London, UK
09:30 Registration and refreshments
10:00 Opening address from the chair
10:10 Bridging the gap between pre-clinical and
clinical CNS trials
• Translational assays of cognition
• Animal models of cognitive impairment
• Use of preclinical biomarkers to enhance assay translation
• Clinical testing of preclinical hypotheses
Dr Mark Tricklebank
Director, Lilly Centre for Cognitive Neuroscience
Eli Lilly and Co
10:50 Reducing the gap between preclinical PK/PD and CNS clinical trials
• Adding value to the discovery of CNS active drugs through the application of mechanistic PK/PD principles
• Understanding the key drivers of in-vivo pharmacological effects and ensuring they are prominent in the lead optimisation paradigm
• Establishing the link between blood concentration, receptor occupancy and drug efficacy
11:30 Morning refreshments
11:50 Novel imaging approaches in clinical trials and the role of an imaging CRO
• Novel Imaging Approaches including Structural, Functional and Molecular in CNS Drug Discovery including PET, DTI, fMRI and vCT.
• Imaging Drug Actions Including Neuroreceptor Mapping
• The role of an Imaging CRO in Managing an Imaging Clinical Trial
Professor Mehdi Adineh
Scientific Director Diagnostic Imaging Core Laboratory
American College of Radiology
12:30 Utilising PET imaging biomarkers
• Dementia: glucose metabolism, amyloid tracers, acetylcholine analogues
• Parkinson’s disease: dopamine synthesis & storage capacity
• Psychiatric disorders: dopamine & serotonin receptor occupancy
• Brain tumours: progression and infiltration
• Tracers and techniques for quantitative standardised analysis will be presented
Dr Karl Herholz
Director, Wolfson Molecular Imaging Centre/ Professor of
Clinical Neuroscience
University of Manchester
13:10 Networking Lunch
14.10 Use of biomarkers for demonstrating CNS effects of drugs early in clinical development
• Using animal PK/PD data to set dose range finding in Phase 1
• Use of QEEG to demonstrate CNS activity
• Computer measures of cognition
• Evoked potentials to demonstrate clinical potential
Dr. Michael G. Palfreyman
Head, Translational R&D, ChemDiv
Executive Program Director, Senior Scientific Advisor, EnVivo Pharmaceuticals
14:50 Recruiting strategies for Huntington’s Disease
clinical trials
• The importance of identifying unique barriers to participation in HD clinical trials
• Grass-roots social marketing for HD trials can speed enrollment:
a pilot study
• Treating the HD trial participant as VIP is a cost-effective approach.
Dr LaVonne Veatch Goodman
Co-founder
Huntington’s Disease Drug Works (HDDW)
15:30 Afternoon refreshments
15:50 Patient recruitment and retention strategies for
CNS clinical trials
• Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
• Strategies for overcoming global CNS patient recruitment challenges
• Updates on evolving trends in patient recruitment and retention methodologies
• Illustrative case studies of effective tactics
Gaynor Anders
Vice President Global Operations
MMG
16.30 Successful strategies for accelerating
patient recruitment
• Preparing for successful enrolment
• The ideal set-up
• Avoiding the pitfalls for a pharma-driven trial
• Enlisting support from patients
Professor Elaine Rankin
Medical Oncology
University of Dundee
17:10 Chair’s closing remarks
17:20 End of conference
Related Reports:
Clinical Trials Market India
Clinical Trials: World Market 2009-2024
Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
Trends in Clinical Trials Strategies to enhance clinical trial design
Medical Device Clinical Trials Destination India
For more information visit
http://www.bharatbook.com/detail.asp?id=128073&rt=Conference-on-CNS-Clinical-Trials.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Conference on Clinical Trials Asia Summit 2010
Clinical trials in India are finally becoming transparent. There has been a dramatic increase in the number of trials that have got officially registered in Clinical Trials Registry-India (CTRI). According to records collected by the Indian Council of Medical Research and the Drug Controller General's office, between July-December 2007, only 11 trials were registered. The number increased to 137 between Jan-Dec 2008 and then to an all-time high of 546 between Jan-Dec 2009. This year, while January saw 58 trials registered, February recorded 60. India has all the competitive advantages for conducting clinical trials. As the country is increasingly becoming a favoured destination for clinical trials, a gap analysis needs to be done to scale up all resources for clinical trials. This scale up is essential for India to cope with the large global clinical trial projects. It is no coincidence over the last decade or more of economic liberalization, and years of unprecedented growth, that India and parts of South Asia are becoming a preferred clinical research destination for multinational pharmaceutical and biotechnology corporations.
CTAS 2010 will examine the current issues faced in clinical trials operations, addressing the risks, timeline and budget stipulations, while effectively tackling key challenges in overcoming trials agreement and site contract arbitration problems. This summit will discuss the operational element of trial site management, strategic partnership with CROs and SMOs, patient, talent & investigators management in order to improve & optimise the overall drug development effectiveness and ROI. Discover on how to implement and benefit from electronic data management & monitoring cost effectively. This conference will be shared by leading industrial practitioners across the region to promote practical discussions; especially on the know-how to manage needs, variability of different countries and institutions to enhance clinical operational excellence and vigilance. Attendees will have the chance to learn, network and benchmark against the global top pharmas and local industry leaders on the best practices in talent, site, budget and performance management in clinical trials. The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China and also addressing risk/benefit balance, anecdotal experiences of the multinational pharmaceutical industry in India and China, selection and role of CROs, logistics of operations, clinical trials management, government policies and pharmacovigilance.
CTAS 2010 will provide you with the data that you need to recognize this complex and rapidly-expanding sector. Knowing the future market, and what impact will that have on future business opportunities? This is your opportunity to stay ahead by learning the latest trends and networking with the trend setters. It gives us immense pleasure in welcoming you to the Clinical Trials Asia Summit '2010.
Key Speakers Include:
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy’s,
Bakulesh Khamar, Executive Director – Research Cadila,
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis,
Mohan Bangalore, Senior Director & Site Head, Pfizer,
Parminder Kaur, Managing Director, RegPak BioPharma, Consulting, (Netherlands),
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
Arun Bhatt, President, Clininvent Research,
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai, Associates,
Sanjay Zodpey, Director, Indian Institute of Public Health,
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation),
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline,
Roopa Basrur, Associate Director - Clinical Writing and Document, Quality, Pfizer,
Yamin ’Mo’ Khan, Executive Vice President, Clinical Development Pharma-Olam (U.K),
Marcus Hompesch, President – CEO, Clinical Research, (USA),
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
Mala Srivastava, Partner, Nextvel Consulting,
R Ezhil Arasan, Managing Director, VRE Research Laboratories,
(Former Head of Medical Affairs & Differentiated Products, Development at Dr.Reddy's)
Key Themes Discussed at this conference:
*
Current trends of clinical trials environment.
*
How can you take advantage of the global market for clinical trials?
*
Discovering technologies and strategies for successful clinical trial management.
*
Analyzing the successes and challenges of Phase I and Phase II clinical trials.
*
Setting up clinical trial research hub & techniques for applying risk management principles.
*
Discover how to improve your supplier-client relationships.
*
Complete trials on schedule & budget by overcoming hurdles in investigator/patient recruitment.
*
Avoiding potential pitfalls of trials agreement.
*
Gather the latest regulatory updates impacting global and Indian clinical development.
*
Explore innovative strategies for outsourcing, what should you be looking for in a CRO?
*
Improving and optimizing site management and overall productivity of clinical operations.
*
Data management, CMC SCM, operational requirements & CRO infrastructure in India & South Asia.
*
Optimising clinical trials operation effectiveness and ROI through strategic site, patient, data and risk management in the regulated markets.
*
What are the issues with off-shoring trials to countries such as India & South Asia? – Solutions?
*
Working with limited budget to ensure on time study completion.
*
Motivating and managing clinical project teams to improve timeline and progress.
*
Exploring the efficacy and safety of new interventions in clinical trials.
*
Drawing and retaining clinical talent pool to minimise turnover in clinical studies.
*
Next generation of clinical trials – How big will the market be?
Who Should Attend:
*
Vice Presidents,
*
Directors Heads & Managers of: Clinical Research & Development,
*
Clinical Research Services,
*
Clinical Operations,
*
Clinical Data Management,
*
Clinical IT,
*
Clinical Trials,
*
Medical Affairs, Regulatory Affairs,
*
Compliance,
*
Quality Control/Assurance/GCP,
*
Clinical Study Design,
*
Safety Surveillance,
*
Subject Recruitment,
*
E-Clinical Systems.
Target Audience - Industry:
*
Pharmaceutical Organisations,
*
Generic pharmaceutical companies,
*
Contract Research Organisations ,
*
Patient Recruitment Companies,
*
Government- Department of Health,
*
Non-profit Organisations/Association,
*
Academics, Consultants.
Why should you attend:
Clinical Trials Asia Summit 2010 - "Improving clinical practice & trial success rates with improved technologies, strategies & alliance management"
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time meet the leading international vendors. showcasing the technology of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and technologies in the high-level conference.
DAY 1
19th August 2010,
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
09:40 – Examining the evolution of clinical trials.
*
Where does India stand in the current global clinical trials market?
*
How can you take advantage of the global market for clinical trials?
*
Identify the significance of the clinical trial in India and South Asia market
*
Emerging technologies that can be deployed to generate revenue.
*
Allied services - Data Management & IT services – Can they play significant role in outsourcing clinical trials?
10:20 Changing concept of conducting clinical trials.
*
Challenges in conduct of investigator initiated research.
*
Biomarkers and newer endpoints in oncology.
*
Structure of existing system for training and monitoring staff performance.
*
What are the common problems of staff monitoring and effective solutions to minimise cost for your trials.
*
Challenges in conducting medical device trials.
11:00 – Morning coffee & Discussion.
11:20 – “Factors limiting acceptability of foreign clinical data: EMEA perspective”
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands).
12:00 – Panel Discussion: Evaluating key emerging markets for improved strategy.
*
Which emerging markets are hottest today?
*
Offshoring - Balancing the right opportunities and risks.
*
What makes each market unique and how do markets compare?
*
Successful budget development & analysis - How do sponsors develop study budgets? How do sites price their services?
*
How to go about tracking & collecting payments properly?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
*
Arun Bhatt, President, Clininvent Research,
*
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands),
*
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
*
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
12:40 – Networking lunch.
14:00 – Impact of advanced technology in today's clinical trials.
*
Enable more reliable, smaller, faster, safer trials.
*
Benefits of Information Technology in clinical trials - (EDC), (CTMS), (CDMS), (DBMS).
*
Overcoming issues related with managing security, confidentiality and ethical concerns.
14:40 – Relationships: Sponsor – Site - CRO.
*
Three-way relationship between sponsors, sites and CROs realistic expectations, clear communications, shared understandings,
practical policies, and efficient problem resolution.
*
Identifying the anticipated advantages of a collaborative clinical trial alliance for greater efficiency and cost reduction.
*
Developing programs for successful partnership.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Arun Bhatt, President, Clininvent Research.
15:20 – Afternoon tea.
15:40 – Panel Discussion: Overcoming regulatory challenges in Asian clinical trials.
*
Introducing recent developments in regulatory affairs and legal challenges for clinical trials.
*
Understanding how Indian companies can work in harmony with the European legal framework.
*
Analysing the current scope and strategies of pharmaceutical / biopharmaceutical regulatory harmonization
*
Government incentives for Clinical Research in India.
*
Quality standards in clinical trials.
Moderator –
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates.
Panelists –
Sanjay Zodpey, Director, Indian Institute of Public Health,
16:20 – Safety data Management.
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
17:00 - Start-up teams to manage clinical trials: Advantages and Limitations.
*
Structure and set-up of an effective start-up team.
*
Communication channels between start-up team, operations and Investigator sites.
*
Advantages and Limitations of managing projects under above structure.
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
17:30 - Logistics as a facilitator of growth in the pharma industry.
*
What are the current logistics challenges in pharma industry?
*
What are the recent applications of technology to aid the Clinical SCM?
*
Secure strategies – for maintaining your materials during transits.
*
Efficiency of a potential logistics – transforming the pharma sector.
18:00 - Chairperson's closing remarks and end of conference.
18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting...
DAY 2
20 th August 2010
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
R Ezhil Arasan, Managing Director, VRE Research Laboratories.
(Former Head of Medical Affairs & Differentiated Products Development at Dr.Reddy's)
09:40 – Opportunity trials of Clinical Research in India: Focusing on Phase I and Phase II
*
Reviewing the phase I and II clinical research environment in India.
*
Focus on related business models in conducting clinical trials in India.
*
Evaluating the opportunities of potential collaborations.
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
10:20: Clinical Data Management (CDM) – Guidelines for a successful future.
Safety data management.
*
Good data review and validation practices.
*
Challenges! In medical coding.
*
Consideration in database designing & edit check programming.
*
Good programming practices and where can one go wrong in query management?
*
Developing protocols that generate useful data, practical for sites to implement, acceptable to subjects, and work internationally.
11:00 – Morning coffee & discussion.
11:20 – Innovative designing of clinical trials.
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy's,
12:00 – Panel Discussion: Sourcing the right partners, Sponsor – Vendor partnerships.
*
How to work with your sponsor for a profitable study.
*
What do CRO look for in a good sponsor?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
Mohan Banglore, Senior Director & Site Head, Pfizer,
Marcus Hompesch, President – CEO, Profile Institute - Clinical Research, (USA),
Yamin 'Mo' Khan, Executive Vice President, Clinical Development, Pharm-Olam (UK),
Mala Srivastava, Partner, Nextvel Consulting,
12:40 – Networking lunch.
14:00 – Challenges of conducting Phase III cancer trails in India.
Bakulesh Khamar, Executive Director – Research, Cadila,
14:40 – Conducting large-scale community trials.
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation).
15:20 – Afternoon tea.
15:40 – Exploring the efficacy and safety of new interventions in clinical trials.
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline.
16:20 - Setting up a medical writing unit in India.
*
Outsourcing medical writing to India – a novel business model.
*
What factors are important at start-up and later on?
*
Measuring success in a subjective domain – metrics.
*
Challenges and solutions.
Roopa Basrur, Associate Director - Clinical Writing and Document Quality, Pfizer.
17:00 – Panel Discussion – SWOT analysis - Strength, Weakness, Opportunities & Threats of Clinical Trials in India (Overall review of this Clinical Trials Asia Summit 2010 conference).
*
Identifying market potential strengths and weakness.
*
Benefits of India - reducing costs, accelerating time to market?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
Moderator:
Panellists:
Thuppil Venkatesh, Prof. St.John's Medical College & Principal Advisor, Quality Council of India,
17:30 Chairperson's closing remarks and end of conference.
Book Now:
1 Day Conference............Fee INR. 8824.00
2 Day Conference............Fee INR. 11030.00
For more information visit
http://www.bharatbook.com/detail.asp?id=104776&rt=Conference-on-Clinical-Trials-Asia-Summit-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
CTAS 2010 will examine the current issues faced in clinical trials operations, addressing the risks, timeline and budget stipulations, while effectively tackling key challenges in overcoming trials agreement and site contract arbitration problems. This summit will discuss the operational element of trial site management, strategic partnership with CROs and SMOs, patient, talent & investigators management in order to improve & optimise the overall drug development effectiveness and ROI. Discover on how to implement and benefit from electronic data management & monitoring cost effectively. This conference will be shared by leading industrial practitioners across the region to promote practical discussions; especially on the know-how to manage needs, variability of different countries and institutions to enhance clinical operational excellence and vigilance. Attendees will have the chance to learn, network and benchmark against the global top pharmas and local industry leaders on the best practices in talent, site, budget and performance management in clinical trials. The conference aims to provide a detailed analysis of what it takes to conduct clinical trials from a biopharmaceuticals and vaccines perspective in India and China and also addressing risk/benefit balance, anecdotal experiences of the multinational pharmaceutical industry in India and China, selection and role of CROs, logistics of operations, clinical trials management, government policies and pharmacovigilance.
CTAS 2010 will provide you with the data that you need to recognize this complex and rapidly-expanding sector. Knowing the future market, and what impact will that have on future business opportunities? This is your opportunity to stay ahead by learning the latest trends and networking with the trend setters. It gives us immense pleasure in welcoming you to the Clinical Trials Asia Summit '2010.
Key Speakers Include:
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy’s,
Bakulesh Khamar, Executive Director – Research Cadila,
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis,
Mohan Bangalore, Senior Director & Site Head, Pfizer,
Parminder Kaur, Managing Director, RegPak BioPharma, Consulting, (Netherlands),
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
Arun Bhatt, President, Clininvent Research,
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai, Associates,
Sanjay Zodpey, Director, Indian Institute of Public Health,
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation),
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline,
Roopa Basrur, Associate Director - Clinical Writing and Document, Quality, Pfizer,
Yamin ’Mo’ Khan, Executive Vice President, Clinical Development Pharma-Olam (U.K),
Marcus Hompesch, President – CEO, Clinical Research, (USA),
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
Mala Srivastava, Partner, Nextvel Consulting,
R Ezhil Arasan, Managing Director, VRE Research Laboratories,
(Former Head of Medical Affairs & Differentiated Products, Development at Dr.Reddy's)
Key Themes Discussed at this conference:
*
Current trends of clinical trials environment.
*
How can you take advantage of the global market for clinical trials?
*
Discovering technologies and strategies for successful clinical trial management.
*
Analyzing the successes and challenges of Phase I and Phase II clinical trials.
*
Setting up clinical trial research hub & techniques for applying risk management principles.
*
Discover how to improve your supplier-client relationships.
*
Complete trials on schedule & budget by overcoming hurdles in investigator/patient recruitment.
*
Avoiding potential pitfalls of trials agreement.
*
Gather the latest regulatory updates impacting global and Indian clinical development.
*
Explore innovative strategies for outsourcing, what should you be looking for in a CRO?
*
Improving and optimizing site management and overall productivity of clinical operations.
*
Data management, CMC SCM, operational requirements & CRO infrastructure in India & South Asia.
*
Optimising clinical trials operation effectiveness and ROI through strategic site, patient, data and risk management in the regulated markets.
*
What are the issues with off-shoring trials to countries such as India & South Asia? – Solutions?
*
Working with limited budget to ensure on time study completion.
*
Motivating and managing clinical project teams to improve timeline and progress.
*
Exploring the efficacy and safety of new interventions in clinical trials.
*
Drawing and retaining clinical talent pool to minimise turnover in clinical studies.
*
Next generation of clinical trials – How big will the market be?
Who Should Attend:
*
Vice Presidents,
*
Directors Heads & Managers of: Clinical Research & Development,
*
Clinical Research Services,
*
Clinical Operations,
*
Clinical Data Management,
*
Clinical IT,
*
Clinical Trials,
*
Medical Affairs, Regulatory Affairs,
*
Compliance,
*
Quality Control/Assurance/GCP,
*
Clinical Study Design,
*
Safety Surveillance,
*
Subject Recruitment,
*
E-Clinical Systems.
Target Audience - Industry:
*
Pharmaceutical Organisations,
*
Generic pharmaceutical companies,
*
Contract Research Organisations ,
*
Patient Recruitment Companies,
*
Government- Department of Health,
*
Non-profit Organisations/Association,
*
Academics, Consultants.
Why should you attend:
Clinical Trials Asia Summit 2010 - "Improving clinical practice & trial success rates with improved technologies, strategies & alliance management"
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time meet the leading international vendors. showcasing the technology of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and technologies in the high-level conference.
DAY 1
19th August 2010,
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
09:40 – Examining the evolution of clinical trials.
*
Where does India stand in the current global clinical trials market?
*
How can you take advantage of the global market for clinical trials?
*
Identify the significance of the clinical trial in India and South Asia market
*
Emerging technologies that can be deployed to generate revenue.
*
Allied services - Data Management & IT services – Can they play significant role in outsourcing clinical trials?
10:20 Changing concept of conducting clinical trials.
*
Challenges in conduct of investigator initiated research.
*
Biomarkers and newer endpoints in oncology.
*
Structure of existing system for training and monitoring staff performance.
*
What are the common problems of staff monitoring and effective solutions to minimise cost for your trials.
*
Challenges in conducting medical device trials.
11:00 – Morning coffee & Discussion.
11:20 – “Factors limiting acceptability of foreign clinical data: EMEA perspective”
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands).
12:00 – Panel Discussion: Evaluating key emerging markets for improved strategy.
*
Which emerging markets are hottest today?
*
Offshoring - Balancing the right opportunities and risks.
*
What makes each market unique and how do markets compare?
*
Successful budget development & analysis - How do sponsors develop study budgets? How do sites price their services?
*
How to go about tracking & collecting payments properly?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
*
Arun Bhatt, President, Clininvent Research,
*
Parminder Kaur, Managing Director, RegPak BioPharma Consulting, (Netherlands),
*
Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Limited,
*
Ramesh Jagannathan, Director-Clinical Research, AstraZeneca,
12:40 – Networking lunch.
14:00 – Impact of advanced technology in today's clinical trials.
*
Enable more reliable, smaller, faster, safer trials.
*
Benefits of Information Technology in clinical trials - (EDC), (CTMS), (CDMS), (DBMS).
*
Overcoming issues related with managing security, confidentiality and ethical concerns.
14:40 – Relationships: Sponsor – Site - CRO.
*
Three-way relationship between sponsors, sites and CROs realistic expectations, clear communications, shared understandings,
practical policies, and efficient problem resolution.
*
Identifying the anticipated advantages of a collaborative clinical trial alliance for greater efficiency and cost reduction.
*
Developing programs for successful partnership.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Arun Bhatt, President, Clininvent Research.
15:20 – Afternoon tea.
15:40 – Panel Discussion: Overcoming regulatory challenges in Asian clinical trials.
*
Introducing recent developments in regulatory affairs and legal challenges for clinical trials.
*
Understanding how Indian companies can work in harmony with the European legal framework.
*
Analysing the current scope and strategies of pharmaceutical / biopharmaceutical regulatory harmonization
*
Government incentives for Clinical Research in India.
*
Quality standards in clinical trials.
Moderator –
Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates.
Panelists –
Sanjay Zodpey, Director, Indian Institute of Public Health,
16:20 – Safety data Management.
Darshan Bhatt, Consultant, Patient Safety and Pharmacovigilance,
17:00 - Start-up teams to manage clinical trials: Advantages and Limitations.
*
Structure and set-up of an effective start-up team.
*
Communication channels between start-up team, operations and Investigator sites.
*
Advantages and Limitations of managing projects under above structure.
Larisa Nagra Singh, General Manager and Project Director, Voisin Consulting Life Science,
17:30 - Logistics as a facilitator of growth in the pharma industry.
*
What are the current logistics challenges in pharma industry?
*
What are the recent applications of technology to aid the Clinical SCM?
*
Secure strategies – for maintaining your materials during transits.
*
Efficiency of a potential logistics – transforming the pharma sector.
18:00 - Chairperson's closing remarks and end of conference.
18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting...
DAY 2
20 th August 2010
08:30 – Coffee and registration.
09:30 – Chair's opening remarks.
R Ezhil Arasan, Managing Director, VRE Research Laboratories.
(Former Head of Medical Affairs & Differentiated Products Development at Dr.Reddy's)
09:40 – Opportunity trials of Clinical Research in India: Focusing on Phase I and Phase II
*
Reviewing the phase I and II clinical research environment in India.
*
Focus on related business models in conducting clinical trials in India.
*
Evaluating the opportunities of potential collaborations.
Deven Parmar Vice President - Clinical Research & Pharmacovigilance, Wockhardt,
10:20: Clinical Data Management (CDM) – Guidelines for a successful future.
Safety data management.
*
Good data review and validation practices.
*
Challenges! In medical coding.
*
Consideration in database designing & edit check programming.
*
Good programming practices and where can one go wrong in query management?
*
Developing protocols that generate useful data, practical for sites to implement, acceptable to subjects, and work internationally.
11:00 – Morning coffee & discussion.
11:20 – Innovative designing of clinical trials.
Akhilesh Sharma, Vice President & Global head Clinical management & Global Pharmacovigilance, Dr. Reddy's,
12:00 – Panel Discussion: Sourcing the right partners, Sponsor – Vendor partnerships.
*
How to work with your sponsor for a profitable study.
*
What do CRO look for in a good sponsor?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
*
Quantitative analysis reveals rapid changes in the industry and trends for the future. How can sponsors, sites and CROs meet the challenges?
Moderator –
Shashidhar Rao, India Operations Head (IID and IA&R), Novartis.
Panelists –
Mohan Banglore, Senior Director & Site Head, Pfizer,
Marcus Hompesch, President – CEO, Profile Institute - Clinical Research, (USA),
Yamin 'Mo' Khan, Executive Vice President, Clinical Development, Pharm-Olam (UK),
Mala Srivastava, Partner, Nextvel Consulting,
12:40 – Networking lunch.
14:00 – Challenges of conducting Phase III cancer trails in India.
Bakulesh Khamar, Executive Director – Research, Cadila,
14:40 – Conducting large-scale community trials.
S.K.Bhattacharya, Medical Officer, Depart of Communicable Diseases, WHO (World Health Organisation).
15:20 – Afternoon tea.
15:40 – Exploring the efficacy and safety of new interventions in clinical trials.
Shailesh Mehta, Director Clinical R&D and Med Affairs, South Asia, Glaxosmithkline.
16:20 - Setting up a medical writing unit in India.
*
Outsourcing medical writing to India – a novel business model.
*
What factors are important at start-up and later on?
*
Measuring success in a subjective domain – metrics.
*
Challenges and solutions.
Roopa Basrur, Associate Director - Clinical Writing and Document Quality, Pfizer.
17:00 – Panel Discussion – SWOT analysis - Strength, Weakness, Opportunities & Threats of Clinical Trials in India (Overall review of this Clinical Trials Asia Summit 2010 conference).
*
Identifying market potential strengths and weakness.
*
Benefits of India - reducing costs, accelerating time to market?
*
Analysing India's offering in large scale global trials: cost, resources, patient pool.
*
Avoiding mistakes in selecting an outsourcing partner to conduct clinical trials.
Moderator:
Panellists:
Thuppil Venkatesh, Prof. St.John's Medical College & Principal Advisor, Quality Council of India,
17:30 Chairperson's closing remarks and end of conference.
Book Now:
1 Day Conference............Fee INR. 8824.00
2 Day Conference............Fee INR. 11030.00
For more information visit
http://www.bharatbook.com/detail.asp?id=104776&rt=Conference-on-Clinical-Trials-Asia-Summit-2010.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Saturday, July 24, 2010
Global Top 10 Pharmaceutical Companies - Industry, Financial and SWOT Analysis
This report analyzes the global pharmaceutical market in terms of market size, key drivers and resistors, trends and competitive positioning. It includes profiles of the top ten companies in the industry along with 5-year financial analysis and in-depth SWOT analysis.
Scope
* Performance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five years
* Obtain descriptive profiles of the top ten leading players including strategic initiatives undertaken in the last 12 months
* Analysis of the Strengths, Weaknesses, Opportunities and Threats of the top 10 pharmaceutical companies along with business overview and financials
* Benchmark the performance of the top 10 players for the past five years; includes revenue comparison, profitability analysis, industry-specific ratios
Highlights
The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.
The cardiovascular segment was the market''s most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market''s overall value.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.
Reasons to Purchase
* Save time, money and resources on analyzing the top 10 pharmaceutical companies using this report
* Analyze the global pharmaceutical market with key industry metrics including market value, market volume, and growth forecasts
* Assess the intensity of competition based on the 5-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
For more information visit
http://www.bharatbook.com/detail.asp?id=141531&rt=Global-Top-10-Pharmaceutical-Companies-Industry-Financial-and-SWOT-Analysis.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Scope
* Performance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five years
* Obtain descriptive profiles of the top ten leading players including strategic initiatives undertaken in the last 12 months
* Analysis of the Strengths, Weaknesses, Opportunities and Threats of the top 10 pharmaceutical companies along with business overview and financials
* Benchmark the performance of the top 10 players for the past five years; includes revenue comparison, profitability analysis, industry-specific ratios
Highlights
The global pharmaceutical market generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-2008.
The cardiovascular segment was the market''s most lucrative in 2008, generating total revenues of $121.7 billion, equivalent to 19.8% of the market''s overall value.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 3.6% for the five-year period 2008-2013, which is expected to drive the market to a value of $734 billion by the end of 2013.
Reasons to Purchase
* Save time, money and resources on analyzing the top 10 pharmaceutical companies using this report
* Analyze the global pharmaceutical market with key industry metrics including market value, market volume, and growth forecasts
* Assess the intensity of competition based on the 5-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
For more information visit
http://www.bharatbook.com/detail.asp?id=141531&rt=Global-Top-10-Pharmaceutical-Companies-Industry-Financial-and-SWOT-Analysis.html
OR Contact us at
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
Subscribe to:
Posts (Atom)